World News: 10:00 GMT Tuesday 14th January 2020. [WPD Pharmaceuticals via Globe Newswire via SPi World News]
VANCOUVER, British Columbia, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Westcot Ventures Corp (CSE: WBIO) (the “”), a clinical stage pharmaceutical company, announces that it has changed its name from “Westcot Ventures Corp.” to “WPD Pharmaceuticals Inc.” (“”) effective today.
Trading of the Company's common shares will resume under the new name and under the same ticker symbol “WBIO” as of market open January 14, 2020. The new CUSIP will be 92941F105 and the new ISIN number will be CA92941F1053.
The name “WPD” was created through combining the names of Dr. Waldemar Priebe and Dr. Waldemar Debinski, each of whom are highly accomplished translational scientists and inventors of the 101, 102 and 103 compounds in WPD’s portfolio. Dr. Priebe is a world-renowned medicinal chemist and entrepreneur and, most notably, one of the founding scientists of Reata Pharmaceuticals, Inc., a leading Nasdaq-listed pharmaceutical company with a market capitalization of over US$5 Billion. Dr. Priebe is the founder or founding scientist of 6 other pharmaceutical companies, and led the research of WPD’s license partner CNS Pharmaceuticals Inc. in developing its lead drug candidate, Berubicin. Dr. Debinski is an internationally recognized leader in targeted cytotoxic therapies and holds 25 patents on various therapeutics and other cancer-fighting approaches. Dr. Debinski’s patents include a drug candidate that uses specific molecular targets to treat glioblastoma, an incurable primary brain tumor, while being less toxic than radiation and chemotherapy and less invasive than surgery.
In connection with its name change, WPD is proud to announce that it has launched a new website,
“” commented . “
The Company also announces that it has granted 5.6 million options today to purchase common shares of the Company (the “”) to employees, management, officers and consultants of the Company. As WPD continues to grow, the Company intends to continue incentivising its long-term contributors for their dedication and loyalty to the growth of the business.
In accordance with the Company’s stock option plan, each Option will be issued an exercisable at $0.86 and has a term of five years. The Options vesting schedule is as follows:
WPD is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules. WPD has 8 novel drug candidates with 4 that are in clinical development stage and 4 in pre-clinical development. These drug candidates were researched at institutions including MD Anderson Cancer Center, Mayo Clinic and Emory University, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland.
WPD has entered into license agreements with Wake Forest University Health Sciences and sublicense agreements with Moleculin Biotech Inc. and CNS Pharmaceuticals, Inc., respectively, each of which grant WPD an exclusive, royalty-bearing sublicense to certain technologies of the licensor. Such agreements provide WPD with certain research, development, manufacturing and sales rights, among other things.
Mariusz OlejniczakCEO, WDP Pharmaceuticals Inc.
Globe Newswire: 10:00 GMT Tuesday 14th January 2020
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2020. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.